MX2020002086A - Agente terapeutico que contiene antagonista de il-33 para endometriosis. - Google Patents

Agente terapeutico que contiene antagonista de il-33 para endometriosis.

Info

Publication number
MX2020002086A
MX2020002086A MX2020002086A MX2020002086A MX2020002086A MX 2020002086 A MX2020002086 A MX 2020002086A MX 2020002086 A MX2020002086 A MX 2020002086A MX 2020002086 A MX2020002086 A MX 2020002086A MX 2020002086 A MX2020002086 A MX 2020002086A
Authority
MX
Mexico
Prior art keywords
endometriosis
antagonist
therapeutic agent
containing therapeutic
adenomyosis
Prior art date
Application number
MX2020002086A
Other languages
English (en)
Inventor
Tomohiro Yoshimoto
I Violetta Stone
Toru Kato
Koubun Yasuda
Joseph M Palumbo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2020002086A publication Critical patent/MX2020002086A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Proveer un agente terapéutico para endometriosis y adenomiosis uterina. La IL-33 se identificó como un factor que exacerba la endometriosis y la adenomiosis uterina, y se descubrió que un antagonista de IL-33, que es capaz de inhibir la función de IL-33, es útil para tratar, prevenir o aliviar la endometriosis y la adenomiosis uterina.
MX2020002086A 2017-08-31 2018-08-31 Agente terapeutico que contiene antagonista de il-33 para endometriosis. MX2020002086A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762552594P 2017-08-31 2017-08-31
PCT/JP2018/032494 WO2019045075A1 (ja) 2017-08-31 2018-08-31 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤

Publications (1)

Publication Number Publication Date
MX2020002086A true MX2020002086A (es) 2020-10-28

Family

ID=65525625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002086A MX2020002086A (es) 2017-08-31 2018-08-31 Agente terapeutico que contiene antagonista de il-33 para endometriosis.

Country Status (15)

Country Link
US (2) US11492398B2 (es)
EP (1) EP3677281A4 (es)
JP (3) JP7177446B2 (es)
KR (1) KR20200044812A (es)
CN (4) CN111107875A (es)
AU (1) AU2018325645A1 (es)
BR (1) BR112020003458A2 (es)
CA (1) CA3074421A1 (es)
IL (1) IL272864B2 (es)
MX (1) MX2020002086A (es)
PH (1) PH12020500400A1 (es)
SG (1) SG11202001786PA (es)
TW (2) TWI825025B (es)
WO (1) WO2019045075A1 (es)
ZA (1) ZA202001256B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105980556B (zh) 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
EP3851121A4 (en) * 2018-09-14 2022-06-08 Mitsubishi Tanabe Pharma Corporation PHARMACEUTICAL COMPOSITION CONTAINING A HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY
WO2023157895A1 (ja) * 2022-02-17 2023-08-24 国立大学法人 鳥取大学 子宮内膜症又は子宮腺筋症の予防又は治療剤
CN114712509A (zh) * 2022-04-01 2022-07-08 首都医科大学附属北京妇产医院 Il-33拮抗剂的新用途
WO2024005634A1 (en) * 2022-06-28 2024-01-04 Stichting Vumc Anti-angiogenic therapy as treatment for benign uterine disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
KR20140094647A (ko) 1999-03-25 2014-07-30 아비에 도이치란트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
EP2354148B1 (en) 2002-02-13 2013-09-04 Takeshi Imanishi Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
RU2425054C2 (ru) 2005-06-01 2011-07-27 Микромет Аг Антитела против il2
PL2163562T3 (pl) 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2297203A1 (en) 2008-06-30 2011-03-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
CA2734330A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies against sonic hedgehog homolog and uses thereof
ES2655079T3 (es) 2009-09-10 2018-02-16 Merck Sharp & Dohme Corp. Uso de antagonistas de IL-33 para tratar enfermedades fibróticas
CN102596983B (zh) 2009-10-29 2016-06-15 国立大学法人大阪大学 交联型人工核苷和核苷酸
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
CA2885719C (en) 2012-09-21 2017-07-11 Osaka University Oligonucleotide and artificial nucleoside having guanidine bridge
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
CN105980556B (zh) 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
BR112016016020B1 (pt) 2014-01-10 2024-02-27 Anaptysbio, Inc Agente de ligação (il-33) de interleucina-33, célula procariótica isolada, composição e uso do referido agente
WO2016031932A1 (ja) 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
US20160168640A1 (en) * 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
AU2016226414B2 (en) * 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
HUE053097T2 (hu) 2015-03-31 2021-06-28 Medimmune Ltd Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
JP6501650B2 (ja) 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
US10005834B2 (en) * 2015-10-06 2018-06-26 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
WO2018158332A1 (en) 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies
EP3851121A4 (en) 2018-09-14 2022-06-08 Mitsubishi Tanabe Pharma Corporation PHARMACEUTICAL COMPOSITION CONTAINING A HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY

Also Published As

Publication number Publication date
CN115920032A (zh) 2023-04-07
PH12020500400A1 (en) 2021-01-04
TWI825025B (zh) 2023-12-11
CN111107875A (zh) 2020-05-05
IL272864B1 (en) 2023-11-01
CA3074421A1 (en) 2019-02-07
CN115920031A (zh) 2023-04-07
ZA202001256B (en) 2023-10-25
JP7441473B2 (ja) 2024-03-01
BR112020003458A2 (pt) 2020-08-25
CN115920041A (zh) 2023-04-07
TW202306586A (zh) 2023-02-16
JP7177446B2 (ja) 2022-11-24
RU2020108574A3 (es) 2021-09-16
IL272864B2 (en) 2024-03-01
SG11202001786PA (en) 2020-03-30
US20220372130A1 (en) 2022-11-24
AU2018325645A1 (en) 2020-02-27
WO2019045075A1 (ja) 2019-03-07
JPWO2019045075A1 (ja) 2020-08-20
EP3677281A4 (en) 2021-05-12
EP3677281A1 (en) 2020-07-08
JP2024045481A (ja) 2024-04-02
US20200190182A1 (en) 2020-06-18
RU2020108574A (ru) 2021-08-30
JP2022190064A (ja) 2022-12-22
KR20200044812A (ko) 2020-04-29
IL272864A (en) 2020-04-30
TW201919706A (zh) 2019-06-01
US11492398B2 (en) 2022-11-08

Similar Documents

Publication Publication Date Title
PH12020500400A1 (en) Il-33 antagonist-containing therapeutic agent for endometriosis
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
PH12017501155A1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
UA116125C2 (uk) Інгібітори cdc7
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MD4801C1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
IL271680A (en) Compositions and methods for inhibiting expression of HMGB1
TN2017000435A1 (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
PH12017500881B1 (en) Aurora a kinase inhibitor
EP3676395A4 (en) METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF ENDOMETRIOSIS
ZA201705254B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles